New search | Conferencedetail
mail
Print view
 
 

6th Gene Therapy for Rare Disorders 2023

Evvnt Promotion / evvnt
-
20.03.2023 - 23.03.2023  Sheraton Boston Hotel, 39 Dalton St, 02199 Boston, USA
Time: 8:00 am to 5:00 pm
 
Conference themes
2022 has been a landmark year for the global gene therapy space. With August came the green light for bluebird bio's Zynteglo in the US, the first FDA approval for a gene therapy in over three years. Hot off its heels we saw the accelerated approval of another bluebird bio product, Skysona. Overseas, July and August brought EMA approvals for PTC Therapeutics' Upstaza and BioMarin's Roctavian, the first gene therapies for AADC deficiency and Haemophilia A respectively.
Scientific Society
Hanson Wade
Notes
Speakers: Faraz Ali, Chief Executive Officer, Tenaya Therapeutics, Deborah Ascheim, Chief Medical Officer, Stridebio, Eduard Ayuso, Chief Executive and Technology Officer, DiNAQOR, Sudha Babu, Regulatory CMC Leader, Spark Therapeutics and More
 

Enquiries and Registration:

https://go.evvnt.com/1439816-2?pid=4832
Ms. Emily Birt
 
Categories
Health Services, Public Health
Languages
English
Congress fees
USD 2999.00 - USD 7095.00
Participants expected
1000
Organizer contact info
83 Great Titchfield Street
W1W 6RH London
United Kingdom
 
"Going International promotes access to education and training for all regardless of social, geographic and national borders."

Ärztekammer für WienHilfswerk AustriaÖsterreichisches Rotes KreuzCharité International AcademyAnästhesie in Entwicklungsländern e. V.Center of ExcellenceÖsterreichische Gesellschaft für Public HealthOÖ Gebietskrankenkasse, Referat für Wissenschaftskooperation